Information Provided By: 
Fly News Breaks for February 18, 2020
XLRN
Feb 18, 2020 | 07:05 EDT
H.C. Wainwright analyst Edward White raised his price target for Acceleron Pharma to $129 from $90 and reiterates a Buy rating on the shares. The analyst sees an increased probability of success for Reblozyl in myelodysplastic syndromes. He reminds investors that the next upcoming catalyst for Acceleron is the FDA action date of April 4 for Reblozyl for the treatment of anemia in adults with low-to-intermediate risk myelodysplastic syndromes who have ring sideroblasts and require red blood cell transfusions.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
